| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/28/2011 | EP1937827B1 Antibodies and their use in the treatment, prevention and diagnosis of a disease associated with sod1 abnormalities |
| 09/28/2011 | EP1909830B1 Reducing interference between oil-containing adjuvants and surfactant-containing antigens |
| 09/28/2011 | EP1864131B1 Natural ligand of g protein coupled receptor rcc356 and uses thereof |
| 09/28/2011 | EP1734992B1 Improved inactivated fcv vaccines |
| 09/28/2011 | EP1708751B1 Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| 09/28/2011 | EP1567014B1 Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors |
| 09/28/2011 | EP1506005B1 Methods for the in vitro culture of sporozoea sp. and use thereof |
| 09/28/2011 | EP1463531B1 Methods for inhibiting ocular processes |
| 09/28/2011 | EP1421191B1 Humanised antibodies specific for both CD45RB and CD45RO |
| 09/28/2011 | EP1263965B1 Avirulent, immunogenic flavivirus chimeras |
| 09/28/2011 | CN1905899B EphA2 agonistic monoclonal antibodies and methods of use thereof |
| 09/28/2011 | CN1787839B Polysaccharide - staphylococcal surface adhesion carrier protein conjugates for immunization against nosocomial infections |
| 09/28/2011 | CN1750843B Methods and compositions for inducing apoptosis in cancer cells |
| 09/28/2011 | CN1665842B Human IgM antibody inducing apoptosis in HIV-infected cells and remedy for HIV-infection |
| 09/28/2011 | CN102203290A Molecular marker for cancer stem cell |
| 09/28/2011 | CN102203252A Novel immunoadjuvant flagellin-based compounds and use thereof |
| 09/28/2011 | CN102203135A Antibodies against sonic hedgehog homolog and uses thereof |
| 09/28/2011 | CN102203121A Prevention, treatment and diagnosis of p.gingivalis infection |
| 09/28/2011 | CN102202720A Phase-transition polymeric microneedles |
| 09/28/2011 | CN102202693A Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells |
| 09/28/2011 | CN102202690A Oncostatin m as promoter of immunostimulatory activity of human epithelial cells |
| 09/28/2011 | CN102202689A Vaccine |
| 09/28/2011 | CN102202688A Stable, dried rotavirus vaccine, compositions and process for preparation thereof |
| 09/28/2011 | CN102202687A Replication-defective flavivirus vaccines and vaccine vectors |
| 09/28/2011 | CN102202686A Outer membrane vesicle prime - protein boost vaccine |
| 09/28/2011 | CN102202685A Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition |
| 09/28/2011 | CN102202643A Stabilized protein compositions |
| 09/28/2011 | CN102199628A Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |
| 09/28/2011 | CN102199617A Dengue virus subunit vaccine and preparation method thereof |
| 09/28/2011 | CN102199613A High productive capacity HCV mutant of infectious HCV and application thereof |
| 09/28/2011 | CN102199612A Nucleotide sequence used in preparation of Mycobacterium smegmatis vaccine and application thereof |
| 09/28/2011 | CN102199611A Clostridium difficile exotoxin A carboxy-terminal gene sequence with optimized codon and nucleic acid vaccine thereof |
| 09/28/2011 | CN102199593A Method for linking sequences of interest |
| 09/28/2011 | CN102199571A Recombinant Bordetella bronchiseptica strain expressing ORF2 gene fragment of porcine circovirus type 2, vaccine and application |
| 09/28/2011 | CN102199560A Salmonellapullorum attenuated mutagenesis strain delta S6702 (RfaG) and construction method thereof |
| 09/28/2011 | CN102199218A Fusion protein of Her2 antibody and interleukin 2 and application thereof |
| 09/28/2011 | CN102199217A Hepatitis B virus multi-epitope fusion protein and preparation method and application thereof |
| 09/28/2011 | CN102199216A New dendritic cell co-stimulatory molecules |
| 09/28/2011 | CN102199210A Anti-interleukin-8 antibody |
| 09/28/2011 | CN102199209A Anti-interleukin-8 antibody |
| 09/28/2011 | CN102199204A Chicken-origin heat shock protein, and encoding gene and application thereof |
| 09/28/2011 | CN102198275A Recombinant plasmid DNA vaccine for treating hepatitis b |
| 09/28/2011 | CN102198270A Preparation method of aluminum-containing adjuvant hepatitis B vaccine |
| 09/28/2011 | CN102198269A Application of Brucella GroEL protein and method for recombinant expression of Brucella GroEL protein |
| 09/28/2011 | CN102198268A Recombinant Swine pox virus (SPV) vector vaccine for the expression of Streptococcus equi subsp zooepidemicus (SEZ) M-like protein (SzP) |
| 09/28/2011 | CN102198267A Recombinant bacillus calmette guerin vaccine for toxoplamasis and preparation method thereof |
| 09/28/2011 | CN102198266A Cancer antigens based on tumor suppressor gene WT1 product |
| 09/28/2011 | CN102198264A Beta-defensin 15 of specific antibacterial peptides of rat epididymis and application thereof |
| 09/28/2011 | CN101659958B Multi-titer live vaccine as well as preparation method and application thereof |
| 09/28/2011 | CN101570755B Novel gene of virus original protease inhibitor as well as expression and application thereof |
| 09/28/2011 | CN101474208B Classification and production technique of newborn calf serum |
| 09/28/2011 | CN101212984B Process for attaching effector molecules to proteins |
| 09/28/2011 | CN101171031B Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease |
| 09/27/2011 | US8026354 Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use |
| 09/27/2011 | US8026345 Characterization and identification of unique human adiponectin isoforms and antibodies |
| 09/27/2011 | US8026344 Targeted binding agents directed to uPAR and uses thereof |
| 09/27/2011 | US8026342 Compositions and methods for binding sphingosine-1-phosphate |
| 09/27/2011 | US8026341 Transfection complexes |
| 09/27/2011 | US8026224 Tumor cells with increased immunogenicity and uses therfor |
| 09/27/2011 | US8026213 Methods for treating muscle diseases and disorders |
| 09/27/2011 | US8026209 Administering a diagnostic agent with a carrier conjugated to a targeting molecule that binds to a lipopolysaccharide-sensitive polypeptide, which is either up-regulated or down-regulated in ECs by exposure to LPS; delivery into the EC vascular barrier and/or across the EC vascular barrier |
| 09/27/2011 | US8026109 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 09/27/2011 | US8025891 Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia |
| 09/27/2011 | US8025890 Nucleic acids and proteins from streptococcus groups A and B |
| 09/27/2011 | US8025889 Botulinum toxin administration to treat various conditions |
| 09/27/2011 | US8025888 Recovering the protein expressed by open reading frame 2 from porcine circovirus type 2; provide immunogenic composition that comprises PCV2 ORF2 proteins and that are highly stable over a period of 24 months |
| 09/27/2011 | US8025887 Avirulent, immunogenic flavivirus chimeras |
| 09/27/2011 | US8025886 Modified VEGF-A with improved angiogenic properties |
| 09/27/2011 | US8025885 Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use |
| 09/27/2011 | US8025884 Lawsonia intracellularis subunit vaccines |
| 09/27/2011 | US8025883 Antagonists and methods for inhibiting angiogenesis |
| 09/27/2011 | US8025882 Interferon alpha antibodies and their uses |
| 09/27/2011 | US8025881 BMP antibodies and methods of treating kidney disease using the same |
| 09/27/2011 | US8025880 Using heat shock organizing protein (BABA) specific immunoglobulin as diagnostic tool in detection of campylobacter infection |
| 09/27/2011 | US8025878 Protofibril selective antibodies and the use thereof |
| 09/27/2011 | US8025877 Methods of using humanized antibodies and compositions for binding sphingosine-1-phosphate |
| 09/27/2011 | US8025876 Antibodies against a peptide epitope of apolipoprotein B |
| 09/27/2011 | US8025873 Chimeric antigens for eliciting an immune response |
| 09/27/2011 | CA2558805C Anti-myostatin antibodies |
| 09/27/2011 | CA2475448C Method for accessing microbial diversity |
| 09/27/2011 | CA2468849C Surface simulation synthetic peptides useful in the treatment of hyper-variable viral pathogens |
| 09/27/2011 | CA2453486C The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 09/27/2011 | CA2377519C Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies |
| 09/27/2011 | CA2372553C Attenuated microorganisms for the treatment of infection |
| 09/27/2011 | CA2213331C Chemokine receptors 88-2b [ckr-3] and 88c and their antibodies |
| 09/22/2011 | WO2011116387A1 Production of aglycosylated monoclonal antibodies in ciliates |
| 09/22/2011 | WO2011116353A2 Method for regulating survival and memory of t helper 1 cells |
| 09/22/2011 | WO2011116344A2 Targeting cancer stem cells |
| 09/22/2011 | WO2011116299A2 Myeloid derived suppressor cell inhibiting agents |
| 09/22/2011 | WO2011116226A2 Display of antibody fragments on virus-like particles of rna bacteriophages |
| 09/22/2011 | WO2011116212A2 Bone morphogenetic protein receptor binding agents and methods of their use |
| 09/22/2011 | WO2011116189A1 Disrupted adenovirus-based vaccine against drugs of abuse |
| 09/22/2011 | WO2011116094A2 Live attenuated chimeric porcine circovirus vaccine |
| 09/22/2011 | WO2011116090A1 Anti-nerve growth factor (ngf) antibody compositions |
| 09/22/2011 | WO2011116026A2 Inhibitors of beta integrin-g protein alpha subunit binding interactions |
| 09/22/2011 | WO2011116014A2 Humanized antibodies to labyrinthin and uses thereof |
| 09/22/2011 | WO2011115970A1 System and method of preparing and storing activated mature dendritic cells |
| 09/22/2011 | WO2011115583A1 A novel platform for retrovirus-like particle (vlp)-display of vaccine antigens |
| 09/22/2011 | WO2011115483A1 Peptides, conjugates and method for increasing immunogenicity of a vaccine |
| 09/22/2011 | WO2011115271A1 Tumor angiogenesis inhibitor |